These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 26402013

  • 1. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H, Eyjolfsdottir H, Eriksdotter M, Oprica M, Schultzberg M.
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [Abstract] [Full Text] [Related]

  • 2. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, Veerhuis R.
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [Abstract] [Full Text] [Related]

  • 3. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

  • 4. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ.
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z, Ricny J, Kolarova M, Vyhnalek M, Hort J, Laczo J, Sirova J, Ripova D.
    J Alzheimers Dis; 2014 May; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
    Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Toxic Amyloid-β42 Conformer May Accelerate the Onset of Alzheimer's Disease in the Preclinical Stage.
    Futamura A, Hieda S, Mori Y, Kasuga K, Sugimoto A, Kasai H, Kuroda T, Yano S, Tsuji M, Ikeuchi T, Irie K, Ono K.
    J Alzheimers Dis; 2021 Mar; 80(2):639-646. PubMed ID: 33579852
    [Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, Bosch B, Grau-Rivera O, Fernandez-Villullas G, Rami L, Lladó A, Sánchez-Valle R, Molinuevo JL.
    Neurodegener Dis; 2016 Feb; 16(1-2):69-76. PubMed ID: 26560503
    [Abstract] [Full Text] [Related]

  • 18. Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease.
    Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, Forsgren L, Wågberg T, Svensson J, Zetterberg H, Morozova-Roche LA.
    ACS Chem Neurosci; 2016 Jan 20; 7(1):34-9. PubMed ID: 26550994
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
    Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.
    J Alzheimers Dis; 2013 Jan 20; 33(3):807-22. PubMed ID: 23034521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.